Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q1 FY25 Earnings Presentation
28 slides from Concord Biotech's earnings presentation, August 2024
Slide 1: Concord Biotech Limited Investor Presentation – August 2024
` Concord Biotech Limited Investor Presentation – August 2024
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 3: Q1 FY25 Key Financial Highlights
` Q1 FY25 Key Financial Highlights
Slide 4: Q1 FY25 Segment wise Revenue Split (1/2)
Q1 FY25 Segment wise Revenue Split (1/2) API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +5% +43% +11% 163.6 171.1 44.8 215.8 194.8 31.2 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs
Slide 5: Q1 FY25 Segment wise Revenue Split (2/2)
Q1 FY25 Segment wise Revenue Split (2/2) API : Formulation (Q1FY25) Domestic : Export (Q1FY25) 16% 21% 41% 46% Q1FY24 Q1FY25 Q1FY24 Q1FY25 54% 59% 79% 84% API Formulation Domestic Exports 5
Slide 6: Q1 FY25 Consolidated Financial Highlights
Q1 FY25 Consolidated Financial Highlights Revenue (Rs. in Crs) EBIDTA (Rs. in Crs) PAT (Rs. in Crs) +11% +13% +9% 215.8 81.3 59.6 194.8 72.2 54.5 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Q1FY24 Q1FY25 Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) 79.3% 77.6% 37.0% 37.7% 28.0% 27.6% Q1FY24 Q1FY25 Q1FY2
Slide 7: Q1 FY25 Consolidated Profit & Loss Account
Q1 FY25 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q1FY25 Q1FY24 Y-o-Y FY24 FY23 Y-o-Y Revenue from Operations 215.8 194.8 11% 1,016.9 853.2 19% Cost of Goods Sold 48.3 40.4 229.2 180.2 Gross Profit 167.5 154.4 8% 787.7 673.0 17% Gross Profit Margin 77.6% 79.3% 77.5% 78.9% Emplo
Slide 8: Management Commentary
Management Commentary Commenting on the Q1 FY25 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, Our revenues for Q1FY25 stood Rs. 215 crores, marking a 11% growth compared to same period last year. Our EBITDA margins for
Slide 9: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (in Rs. Crs) Mar-24 Mar-23 Equity & Liabilities (in Rs. Crs) Mar-24 Mar-23 Non - Current Assets 804.5 786.3 Total Equity 1,526.6 1,290.0 Property Plant & Equipment's 571.7 592.5 Share Capital 10.5 10.5 CWIP 211.5 172.7 Other Equity 1,516.2 1,279.5 Intangible assets
Slide 10: Abridged Cashflow Statement
Abridged Cashflow Statement Particulars (in Rs. Crs) FY24 FY23 Net Profit Before Tax 412.6 322.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 37.4 46.6 Operating profit before working capital changes 450.0 368.6 Changes in working capital -81.2 -52.3 Cash generated from Ope
Slide 11: Company Overview
` Company Overview
Slide 12: About Concord Biotech
About Concord Biotech Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Fermentation-based API R & D Capabilities Competent Management Among few companies global
Slide 13: Concord Biotech Business Snapshot
Concord Biotech Business Snapshot Product 30 135+ 20%+ Portfolio Fermentation- based Market Share by APIs API DMF’s Volume in 5 Molecules Infrastructure 1250m3 3 ~802 mn Total Installed Manufacturing facilities Units Formulation Fermentation Capacity located at Dholka, Valthera Capacity and Limbasi
Slide 14: Overview of API & Formulation
Overview of API & Formulation API Formulation Commercialization of Formulations segment One of the leading global developers and in 2016 to capitalize on the benefits of manufacturers of Fermentation-based APIs backward integration Operate through B2B model across Focus on Niche Fermentation API’s w
Slide 15: State-of-the-art Manufacturing Facilities
State-of-the-art Manufacturing Facilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat Unit III (API) – Limbasi, Gujarat + Upcoming Injectable Facility • Operations commenced in year 2000 • Operations commenced in year 2016 • Operations commenced in year 2021 • Spread ac
Slide 16: Strong R&D Capabilities
Strong R&D Capabilities R&D Initiatives: Investments in R&D (in Crores) New Product Development 30 173* Cost Improvement 26 R&D Employee Strength 23 Process Improvement > 135 13 Technology Transfer API DMFs Scale-up Initiatives 6/4 Enhancement of Backward Integration ANDA approved products/ FY21 FY2
Slide 17: Diversified Customer Base
Diversified Customer Base Concord Biotech’s Customer Profile Only supplier of complete portfolio of fermentation based Immuno-suppressant API’s 70+ Countries Niche basket of fermentation- based API’s in Oncology Anti Infectives & Anti Fungal 250+ Customers FY20 FY21 FY22 FY23 FY24 Reducing Customer
Slide 18: Paving the Way for Sustainability
Paving the Way for Sustainability Sustainable Manufacturing Global Green Leadership Environmental Conservation We envision a manufacturing process that With our unwavering commitment to Concord Biotech firmly believes in the Our Vision for prioritizes environmental sustainability, sustainability, we
Slide 19: Key Business Differentiators
Concord Biotech Limited Key Business Differentiators
Slide 20: Key Differentiators
Key Differentiators Market Leader in fermentation based Immuno- Strong Presence across suppressant API’s Strong & Consistent Fermentation value chain & Financial Track Record Focus on niche complex fermentation API’s across multiple therapeutic areas High Entry Barriers Wide product portfolio of Uti
Slide 21: Strong Presence Across Complex Fermentation Value Chain
Strong Presence Across Complex Fermentation Value Chain Over 2 Decades Experience in the industry with a demonstrated track 1250 M3 record of developing niche and complex molecules Fermentation Capacity across two API facilities 02 03 30 Fermented based API’s One of leading global developers and man
Slide 22: Creating Significant Entry Barriers
Creating Significant Entry Barriers Significant Complex technical capabilities, difficulties in scaling up operations and substantial capital investment Entry Barriers required have resulted in significant barriers to entry in the fermentation-based API space Complex Process & Technical 01 Portfolio
Slide 23: Wide Spectrum of Niche Fermented API's
Wide Spectrum of Niche Fermented API’s 1 Immunosuppressant 2 ▪ Tacrolimus Oncology 3 ▪ Mycophenolate Mofetil ▪ Temsirolimus Anti-Bacterial 4 ▪ Mycophenolate Sodium ▪ Everolimus ▪ Mupirocin Anti-Fungal 5 ▪ Romidepsin ▪ Cyclosporine ▪ Mupirocin Calcium ▪ Anidulafungin Others ▪ Mitomycin ▪ Sirolimus ▪
Slide 24: DMF Fillings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Immuno- Mycophenolate Sodium ✓ ✓ ✓ ✓ Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ Pimecrolimus ✓ Temsirolimus ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓ Mitomycin ✓ ✓ Dact
Slide 25: Wide Range of Formulation Product Portfolio for India Markets
Wide Range of Formulation Product Portfolio for India Markets Critical Care Nephrology & Organ Transplantation Rheumatology Antifungal Transplant & Immunology Rheumatology & Immunology Antibiotics Chronic Kidney Disease Plasma Products Plasma Products Plasma Products 25
Slide 26: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolate Mofetil Suspension Mycophenolic Acid DR Tablets USP My
Slide 27: Key Growth Drivers
Key Growth Drivers API Marketing existing APIs to Increasing wallet share with Expanding API Portfolio new customers existing customers Formulations Expanding portfolio through own Launching new dosage forms Expanding geographic reach development & in-licensing including injectables in India, EMs an
Slide 28: For further Information, please contact
For further Information, please contact Concord Biotech Limited Investor Relations Advisors Concord Biotech Limited Strategic Growth Advisors Private Limited CIN: L24230GJ1984PLC007440 CIN: U74140MH2010PTC204285 Mr. Lalit Sethi – Chief Financial Officer Mr. Jigar Kavaiya / Mr. Sagar Shroff lalitseth